SecurityAKER / Akers Biosciences Inc. (00973E102)
Institutional Owners22 (1 N-Q Owners)
Institutional Shares9,332,992 - 11.39% (ex. N-Q)
Common Shares Outstanding81,973,964 shares (as of 2017-12-31)
Institutional Value$ 3,499,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

AKER / Akers Biosciences Inc. Institutional Ownership

Akers Biosciences Inc. (NASDAQ:AKER) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,332,992 shares. Largest shareholders include Vanguard Group Inc, Alpha Capital Anstalt, Empery Asset Management, LP, Courage Capital Management Llc, Citadel Advisors Llc, Geode Capital Management, Llc, Northern Trust Corp, Bard Associates Inc, IFP Advisors, Inc, and Bigger Capital Fund L P.
Akers Biosciences Inc. (NASDAQ:AKER) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="AKER / Akers Biosciences Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-05-11 13F-HR HSBC HOLDINGS PLC 31,302 26,302 -15.97 4 22 450.00
2018-05-14 13F-HR BARD ASSOCIATES INC 139,600 121,700 -12.82 19 101 431.58
2018-05-09 13F-HR BlackRock Inc. 15,410 15,410 0.00 2 13 550.00
2018-05-14 13F-HR COURAGE CAPITAL MANAGEMENT LLC 1,032,000 360,428 -65.07 138 299 116.67
2018-05-09 13F-HR NORTHERN TRUST CORP 154,248 128
2018-05-15 13F-HR Bank of New York Mellon Corp 79,843 0 -100.00 11 0 -100.00
2018-05-09 13F-HR IFP Advisors, Inc 83,876 111,876 33.38 11 93 745.45
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 421 379 -9.98 0 0
2018-05-15 13F-HR DEUTSCHE BANK AG\ 243,600 0 -100.00 32 0 -100.00
2017-12-22 SC 13G ALPHA CAPITAL ANSTALT 2,516,635
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 36,378 0 -100.00 5 0 -100.00
2018-05-15 13F-HR Advisor Group, Inc. 29,000 29,000 0.00 4 24 500.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 30,508 322,650 957.59 55 267 385.45
2018-05-15 13F-HR VANGUARD GROUP INC 68,425 2,569,301 3,654.92 9 2,127 23,533.33
2018-02-14 13F-HR MILLENNIUM MANAGEMENT LLC 14,319 0 -100.00 12 0 -100.00
2018-05-14 13F-HR Hudson Bay Capital Management LP 563,075 50,326 -91.06 75 42 -44.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 12,000 313,999 2,516.66 1 260 25,900.00
2018-05-15 13F-HR STATE STREET CORP 29,400 24
2018-05-15 13F-HR UBS Group AG 4,111 0 -100.00 1 0 -100.00
2018-02-28 N-Q Ishares Trust (see advisory)
2018-05-14 13F-HR Renaissance Technologies LLC 243,600 0 -100.00 33 0 -100.00
2018-05-07 SC 13G/A Bigger Capital Fund L P 1,953,006 100,000 -94.88
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 230 230 0.00 0 0
2018-05-04 13F-HR SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) 2,100 10,100 380.95 0 8
2018-05-14 13F-HR Virtu Financial LLC 254,338 0 -100.00 34 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 64,965 64,965 0.00 9 54 500.00
2018-05-15 13F-HR JANE STREET GROUP, LLC 34,452 29
2018-01-18 SC 13G/A Empery Asset Management, LP 724,200 2,491,591 244.05

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.


  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( AKER / Akers Biosciences Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Your Daily Pharma Scoop: Reata Provides Update, Assembly Biosciences Data, Bellicum's BPX-501

2018-04-13 seekingalpha
Today we will discuss Reata Pharmaceuticals (RETA), which provided an update on the phase 2 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome. (63-13)

Akers Biosciences (AKER) CEO John Gormally on Q4 2017 Results - Earnings Call Transcript

2018-04-03 seekingalpha
Good morning, and welcome to the Akers Biosciences Conference Call to discuss 2017 Earnings. As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference, Ben Simons with Akers Corporate Communications team. (3-14)

Your Daily Pharma Scoop: Flex Pharma Data, Protagonist Setback, ImmunoGen Results

2018-03-27 seekingalpha
Flex Pharma (NASDAQ:FLKS) shares moved up sharply in early trading on Monday after the company announced positive top-line data from the phase 2 study of FLKS-787 in multiple sclerosis (NYSE:MS) patients with frequent muscle cramps/spasms and spasticity. (110-1)

CUSIP: 00973E102